Acute leukemia in children with down syndrome

Haematologica

Volumn 95, Issue 7, 2010, Pages 1043-1045

  Xavier, Ana C ^a   Taub, Jeffrey W ^b,c,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; CYSTATHIONINE BETA SYNTHASE; CYTARABINE; CYTIDINE DEAMINASE; DAUNORUBICIN; HEAT SHOCK PROTEIN 70; JANUS KINASE 2; METHOTREXATE; PROTEIN BCL 2; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOMYOPATHY; CHILDHOOD LEUKEMIA; CHROMOSOME 21; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DISEASE ASSOCIATION; DOWN SYNDROME; DRUG FATALITY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG UPTAKE; EDITORIAL; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INFECTION; LIVER TOXICITY; MUCOSA INFLAMMATION; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; CHILD; COMPLICATION; FORECASTING; GENETICS; LEUKEMIA; TOXICITY;

ACUTE DISEASE; CHILD; DOWN SYNDROME; FORECASTING; HUMANS; LEUKEMIA; METHOTREXATE;

EID: 77954530697     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.024968     Document Type: Editorial

References (36)

1. Cannon HE. Acute lymphatic leukemia: report of a case in an eleventh month Mongolian idiot. New Orleans Med Surg J. 1930; 94(3):289-93.
2. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992;80(9):2210-4.
3. Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group studies 2861 and 2891. Blood. 1998;91(2):608-15.
4. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128(6):797-804.
5. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005; 19(8):1355-60.
6. Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child. 1990; 65(2):212-6.
7. Dordelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia. 1998;12(5):645-51.
8. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005; 106(13):4043-9.
9. Peeters M, Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr. 1987; 146(4):416-22.
10. Ragab AH, Abdel-Mageed A, Shuster JJ, Frankel LS, Pullen J, van Eys J, et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome. A Pediatric Oncology Group study. Cancer. 1991; 67(4):1057-63.
11. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32(1): 148-52.
12. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997; 16(13):3965-73.
13. Cabelof DC, Patel HV, Chen Q, van Remmen H, Matherly LH, Ge Y, et al. Mutational spectrum at GATA1 provides insights into mutage-nesis and leukemogenesis in Down syndrome. Blood. 2009;114(13): 2753-63.
14. Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94(4):1393-400.
15. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003;21(18):3415-22.
16. Hasle H, Abrahamsson J, Arola M, Karow A, O'Marcaigh A, Reinhardt D, et al. Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia. 2008;22(7): 1428-30.
17. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res. 2004;64(2):728-35.
18. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood. 2006;107(4):1570-81.
19. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99(1):245-51.
20. Valle M, Plon SE, Rabin KR. Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res. 2009;33(2):336-9.
21. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood. 2010 May 4. [Epub ahead of print]
22. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372(9648):1484-92.
23. Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646-8.
24. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-6.
25. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, et al. Down syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the iBFM Study Group. Blood. 2010;115(5):1006-17.
26. Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010 Apr 8. [Epub ahead of print]
27. Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010 Feb 4. [Epub ahead of print]
28. Kalwinsky DK, Raimondi SC, Bunin NJ, Fairclough D, Pui CH, Relling MV, et al. Clinical and biological characteristics of acute lym-phocytic leukemia in children with Down syndrome. Am J Med Genet Suppl. 1990;7:267-71.
29. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. J Pediatr. 2009;155(1):73-8.
30. Maloney KW, Larsen E, Mattano LA, Friedman A, Devidas M, Sather H, et al. Increased infection-related mortality for children with Down syndrome (DS) in contemporary Children's Oncology Group (COG) acute lymphoblastic leukemia (ALL) clinical trials. Blood. 2006; 108 (Abstract).
31. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15(4):1544-52.
32. O'Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, et al. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group study POG 9421. J Clin Oncol. 2008;26(3):414-20.
33. Buitenkamp TD, Mathot RA, de Haas V, Pieters R, Zwaan CM. Methotrexate-induced side effects are not due to differences in phar-macokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica. 2010;95(7):1106-13.
34. Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, et al. Reduced folate carrier gene expression in childhood acute lymhoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res. 1998; 4(9):2169-77.
35. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Shuster JJ, et al. Accumulation of high levels of methotrexate polyg-lutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1992;80(5):1316-23.
36. Stepensky P, Brooks R, Waldman E, Revel-Vilk S, Izraeli S, Resnick I, et al. A rare case of GATA1 negative chemoresistant acute megakary-ocytic leukemia in an 8-month-old infant with trisomy 21. Pediatr Blood Cancer. 2010;54(7):1048-9.